Bio-Rad (BIO) International Revenue Performance Explored

Core Insights - Bio-Rad Laboratories (BIO) reported total revenue of $667.5 million for the quarter ending December 2024, reflecting a 2$146.4 million in revenues, accounting for 21.93% of total revenue, which was a 4.96% shortfall compared to Wall Street's expectation of $154.04 million [5] - EMEA contributed$221.7 million, representing 33.21% of total revenue, exceeding expectations by 6.78% as analysts had projected $207.63 million [6] Future Revenue Projections - For the current fiscal quarter, total revenue is anticipated to be$598.88 million, a 2% decline from the same quarter last year, with expected contributions of 22.3% from Asia ($133.44 million) and 33.5$200.43 million) [7] - The full-year revenue forecast is $2.61 billion, indicating a 1.7$584.15 million) and EMEA 31.9% ($831.63 million) [8] Stock Performance - Bio-Rad's stock has decreased by 24.4% over the past month, contrasting with a 2.3% decline in the Zacks S&P 500 composite [13] - Over the past three months, the company's shares fell by 16.5%, while the S&P 500 declined by only 0.2% [13]